{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:29:45Z","timestamp":1762604985025},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2003,11,1]],"date-time":"2003-11-01T00:00:00Z","timestamp":1067644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NeuroImage"],"published-print":{"date-parts":[[2003,11]]},"DOI":"10.1016\/s1053-8119(03)00405-1","type":"journal-article","created":{"date-parts":[[2003,10,9]],"date-time":"2003-10-09T04:37:07Z","timestamp":1065674227000},"page":"1775-1782","source":"Crossref","is-referenced-by-count":64,"title":["Quantitative assessment of P-glycoprotein function in the rat blood\u2013brain barrier by distribution volume of [11C]verapamil measured with PET"],"prefix":"10.1016","volume":"20","author":[{"given":"Joost","family":"Bart","sequence":"first","affiliation":[]},{"given":"Antoon T.M","family":"Willemsen","sequence":"additional","affiliation":[]},{"given":"Harry J.M","family":"Groen","sequence":"additional","affiliation":[]},{"given":"Winette T.A","family":"van der Graaf","sequence":"additional","affiliation":[]},{"given":"Theodora D","family":"Wegman","sequence":"additional","affiliation":[]},{"given":"Willem","family":"Vaalburg","sequence":"additional","affiliation":[]},{"given":"Elisabeth G.E","family":"de Vries","sequence":"additional","affiliation":[]},{"given":"N.Harry","family":"Hendrikse","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1053-8119(03)00405-1_BIB1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1053\/ctrv.2000.0194","article-title":"The blood-brain barrier and oncology","volume":"26","author":"Bart","year":"2000","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1470-2045(02)00776-3","article-title":"An oncological view on the blood-testis barrier","volume":"3","author":"Bart","year":"2002","journal-title":"Lancet Oncol."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/(SICI)1099-081X(199707)18:5<387::AID-BDD26>3.0.CO;2-X","article-title":"Pharmacokinetics of the enantiomers of verapamil after intravenous and oral administration of racemic verapamil in a rat model","volume":"18","author":"Bhatti","year":"1997","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB4","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1200\/JCO.1996.14.2.610","article-title":"Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer","volume":"14","author":"Boote","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB5","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1073\/pnas.86.2.695","article-title":"Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites","volume":"86","author":"Cordon-Cardo","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S1053-8119(03)00405-1_BIB6","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/sj.leu.2401092","article-title":"Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia","volume":"12","author":"Damiani","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/S1053-8119(03)00405-1_BIB7","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0006-2952(99)00026-X","article-title":"HIV protease inhibitor ritonavir","volume":"57","author":"Drewe","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB8","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/00007691-199506000-00014","article-title":"Oral and intravenous disposition of cyclosporine in psoriatic patients","volume":"17","author":"Galla","year":"1995","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1023\/A:1007093521681","article-title":"Brain microvascular P-glycoprotein and a revised model of multidrug resistance in brain","volume":"20","author":"Golden","year":"2000","journal-title":"Cell Mol. Neurobiol."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB10","first-page":"2411","article-title":"A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier","volume":"59","author":"Hendrikse","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB11","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/sj.bjp.0701979","article-title":"Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualised with positron emission tomography","volume":"124","author":"Hendrikse","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1172\/JCI1269","article-title":"The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors","volume":"101","author":"Kim","year":"1998","journal-title":"J Clin. Invest"},{"key":"10.1016\/S1053-8119(03)00405-1_BIB13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/j.1552-4604.1997.tb04779.x","article-title":"Pharmacokinetics of cyclosporine as a function of energy-protein deficiency in children with chronic renal failure","volume":"37","author":"Lares-Asseff","year":"1997","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB14","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1021\/bi972709x","article-title":"HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter","volume":"37","author":"Lee","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/S1053-8119(03)00405-1_BIB15","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood.V98.12.3212","article-title":"Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia","volume":"98","author":"List","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S1053-8119(03)00405-1_BIB16","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0969-8051(00)00137-2","article-title":"Graphical analysis of PET data applied to reversible and irreversible tracers","volume":"27","author":"Logan","year":"2000","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB17","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/jcbfm.1990.127","article-title":"Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(\u2212)-cocaine PET studies in human subjects","volume":"10","author":"Logan","year":"1990","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1124\/jpet.301.1.7","article-title":"Role of multidrug transporters in pharmacoresistance to antiepileptic drugs","volume":"301","author":"L\u00f6scher","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB19","first-page":"369","article-title":"Modulation of the multidrug resistance P-glycoprotein","volume":"38","author":"Luker","year":"1997","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB20","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1172\/JCI119784","article-title":"Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833","volume":"100","author":"Mayer","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB21","first-page":"1179","article-title":"In vivo uptake of carbon-14-colchicine for identification of tumor multidrug resistance","volume":"35","author":"Mehta","year":"1994","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB22","first-page":"749","article-title":"In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576","volume":"61","author":"Mistry","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB23","first-page":"2964","article-title":"Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance","volume":"60","author":"Newman","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB24","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJMe030023","article-title":"Is refractory epilepsy due to genetically determined resistance to antiepileptic drugs?","volume":"348","author":"Pedley","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB25","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1200\/JCO.1998.16.9.2964","article-title":"Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP","volume":"16","author":"Rowinsky","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB26","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.2042-7158.1998.tb07133.x","article-title":"The absence of stereoselective P-glycoprotein-mediated transport of R\/S-verapamil across the rat jejunum","volume":"50","author":"Sandstrom","year":"1998","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB27","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1172\/JCI118699","article-title":"P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activ-ity of many drugs","volume":"97","author":"Schinkel","year":"1996","journal-title":"J. Clin. Invest"},{"key":"10.1016\/S1053-8119(03)00405-1_BIB28","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/00001813-199909000-00005","article-title":"Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein","volume":"10","author":"Sparreboom","year":"1999","journal-title":"Anticancer Drugs"},{"key":"10.1016\/S1053-8119(03)00405-1_BIB29","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1073\/pnas.84.21.7735","article-title":"Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues","volume":"84","author":"Thiebaut","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S1053-8119(03)00405-1_BIB30","first-page":"670","article-title":"Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with pacli-taxel for advanced breast cancer refractory to paclitaxel","volume":"8","author":"Toppmeyer","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB31","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/jnci\/88.14.994","article-title":"Altered pharmacokinetics of vinblastine in Mdrla P-glycoprotein-deficient mice","volume":"88","author":"van Asperen","year":"1996","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB32","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1023\/A:1011016923346","article-title":"P-glycoprotein inhibition leads to enhanced disruptive effects by anti-microtubule cytostatics at the in vitro blood-brain barrier","volume":"18","author":"van der Sandt","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB33","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2125.1984.tb02536.x","article-title":"Stereoselective first-pass metabolism of highly cleared drugs","volume":"18","author":"Vogelgesang","year":"1984","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/S1053-8119(03)00405-1_BIB34","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0140-6736(93)90319-C","article-title":"Increased neurotoxicity with VAD-cyclosporin in multiple myeloma","volume":"341","author":"Weber","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/S1053-8119(03)00405-1_BIB35","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0969-8043(02)00143-4","article-title":"An improved method for the preparation of [11C]verapamil","volume":"57","author":"Wegman","year":"2002","journal-title":"Appl. Radiat. Isot."}],"container-title":["NeuroImage"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053811903004051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053811903004051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T14:28:08Z","timestamp":1550845688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053811903004051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,11]]}},"alternative-id":["S1053811903004051"],"URL":"https:\/\/doi.org\/10.1016\/s1053-8119(03)00405-1","relation":{},"ISSN":["1053-8119"],"issn-type":[{"value":"1053-8119","type":"print"}],"subject":[],"published":{"date-parts":[[2003,11]]}}}